
Opinion|Videos|May 7, 2024
Evaluating the Impact of Metastatic Breast Cancer on Patients
An expert panel discusses the clinical and economic impact of metastatic breast cancer (mBC) on patients, the prognosis for those with mBC, the three FDA-approved CDK4/6 inhibitors for HR+/HER2- mBC, and the importance of overall survival as a clinical trial endpoint and its relevance to clinical practice.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Baxdrostat as First-in-Class Aldosterone Synthase Inhibitor for Hypertension
2
FDA Approves Immgolis and Immgolis Intri as First Biosimilars to Golimumab Reference Products for RA and UC
3
Insulin Deprescribing Utilizing Continuous Glucose Monitoring With Low-Dose Tirzepatide
4
Why Patients Stop Using Their CGMs—and How Pharmacists Can Help
5




































































































































